Trial · NCT04151667
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | A: Daratumumab & Dexamethasone | Stringent Complete Response | 1 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Stringent Complete Response | 1 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Stringent Complete Response | 0 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Complete Response | 1 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Complete Response | 1 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Complete Response | 0 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Very Good Partial Response | 7 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Very Good Partial Response | 9 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Very Good Partial Response | 5 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Partial Response | 3 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Partial Response | 1 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Partial Response | 1 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Minimal Response | 0 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Minimal Response | 0 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Minimal Response | 0 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Stable Disease | 0 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Stable Disease | 0 | Participants | |
| Overall Response Rate | C: Daratumumab, Dexamethasone and Bortezomib | Stable Disease | 1 | Participants | |
| Overall Response Rate | A: Daratumumab & Dexamethasone | Progressive Disease | 0 | Participants | |
| Overall Response Rate | B: Daratumumab, Dexamethasone and Lenalidomide | Progressive Disease | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04151667/results